Treatment Trials

Search clinical trials by condition, location and status

Free to JoinExpert SupportLatest Treatments

Filter & Search

Clinical Trial Results

Showing 1-3 of 3 trials for Fgfr3-gene-mutation
Recruiting

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Tennessee

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Low-grade NMIBCFGFR Gene AmplificationFGFR Gene AlterationsFGFR3 Gene Alteration
Talk to a Navigator
Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

California · Los Angeles, CA

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

Metastatic Hepatocellular CarcinomaSolid TumorsSolid Tumor, AdultFGFR Gene Amplification
Talk to a Navigator
Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

Florida · Ocala, FL

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.

Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaSolid TumorUrothelial Carcinoma
Talk to a Navigator